Dapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate

达格列净丙二醇一水化物/磷酸西格列汀一水合物

Report date: 2025/03/27 10:48:03

Base Information

Drug NameDapagliflozin Propanediol Hydrate/Sitagliptin Phosphate Hydrate
Drug Alias NameDapagliflozin/sitagliptin FDCFDC of Dapagliflozin and SitagliptinSidapviaSID-1903DW-6012
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsDipeptidyl peptidase IV inhibitors
TargetsSodium/glucose cotransporter 2Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2ST Elevation Myocardial InfarctionMyocardial Infarction
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2023/06/30
Country/TerritoryCanadaGermanySouth Korea
CombinationsYes Dapagliflozin Propanediol MonohydrateSitagliptin Phosphate Monohydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDong Wha Pharm Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca SaDong Wha Pharm Co LtdAstrazeneca Plc +[5] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2ST Elevation Myocardial InfarctionMyocardial Infarction
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia